Results 161 to 170 of about 286,944 (278)

Impact of Atrial Fibrillation on the Risk of Thrombosis and Bleeding for Patients With Polycythemia Vera and Essential Thrombocytosis in the Real World

open access: yes
American Journal of Hematology, Volume 101, Issue 9, Page 2463-2468, September 2026.
Rodrigo Ortega Perez   +19 more
wiley   +1 more source

Hydrocephalus and Diffuse Alveolar Hemorrhage as the Initial Manifestation of Systemic Lupus Erythematosus and Antiphospholipid Syndrome: A Case Report

open access: yesClinical Case Reports, Volume 14, Issue 9, September 2026.
ABSTRACT Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect many systems, such as the central nervous system (CNS), cardiovascular, musculocutaneous, renal, and respiratory systems, etc. SLE can occur alone or in association with other autoimmune diseases, especially antiphospholipid syndrome (APS).
Ehsan Adib   +3 more
wiley   +1 more source

Concomitant Lemierre's Syndrome and Base‐of‐Skull Osteomyelitis Caused by Arcanobacterium haemolyticum, Complicated by Ceftriaxone‐Associated Cholecystitis: A Case Report

open access: yesClinical Case Reports, Volume 14, Issue 9, September 2026.
ABSTRACT Lemierre's syndrome and base‐of‐skull osteomyelitis can occur together in immunocompetent adolescents with Arcanobacterium haemolyticum bacteraemia. Prolonged high‐dose ceftriaxone may precipitate symptomatic cholecystitis. Clinicians should consider A.
Angus Lane, Alexandra Stewart
wiley   +1 more source

Antithrombotic Therapy in Coronary Artery Aneurysm, Ectasia, and Slow Flow: A Systematic Review

open access: yesClinical Cardiology, Volume 49, Issue 9, September 2026.
Antithrombotic therapy for coronary artery aneurysm, coronary artery ectasia, and coronary slow‐flow phenomenon remains insufficiently defined. This review highlights limited and heterogeneous evidence, supporting individualized treatment decisions and the need for stronger comparative studies.
Nasim Kheirandish   +14 more
wiley   +1 more source

Bevacizumab plus nab‐paclitaxel and platinum as second‐line therapy for driver‐gene‐negative non‐squamous non‐small cell lung cancer after immunochemotherapy: A prospective single‐arm single‐centre study

open access: yesClinical and Translational Medicine, Volume 16, Issue 9, September 2026.
This study prospectively evaluated the efficacy and safety of the bevacizumab, nab‐paclitaxel and platinum combination as a second‐line therapy for driver‐gene‐negative advanced non‐squamous non‐small cell lung cancer after immunochemotherapy. The confirmed objective response rate was 46.4%.
Ying Lin   +12 more
wiley   +1 more source

Acute and Chronic Cerebral Hypoperfusion After Flow-Diverter Placement: Is There a Role for Extra-Intracranial Bypass? A Case Series and Narrative Literature Review. [PDF]

open access: yesNeurol Int
Tozzi A   +10 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy